Low-Dose Testosterone for Women: Future Formulations and the Clinical Pipeline

Why the Pipeline Matters for Women Right Now

No FDA-approved testosterone product for women exists in the United States. Full stop. That regulatory gap shapes everything: dosing variability, insurance non-coverage, and a clinical patchwork where women either go without, obtain off-label prescriptions for male-formulated products used at a fraction of the dose, or rely on compounded preparations whose quality control is not federally regulated.

The 2019 Global Consensus Statement on the Use of Testosterone Therapy for Women, co-authored by the International Menopause Society, the Endocrine Society, the British Menopause Society, and 33 other organizations across 13 countries, concluded that testosterone at physiological female doses produces a "small but statistically significant improvement" in sexual desire, arousal, and orgasm in postmenopausal women with HSDD. That statement, by explicitly calling on regulators to approve a women-specific product, put pressure on both industry and the FDA to act. The pressure has been building ever since.

Understanding what is coming next requires understanding why earlier attempts failed, how the current off-label standard works mechanistically, and which formulations are now closest to approval or broad clinical adoption.

How Low-Dose Testosterone Actually Works in Women

The Androgen Receptor Picture

Testosterone binds androgen receptors distributed throughout the brain, genital tissue, bone, and muscle. In women, roughly half of circulating testosterone is produced in the ovaries and the other half in the adrenal glands, with peripheral conversion from androstenedione adding a smaller share. The brain regions governing sexual motivation, particularly the hypothalamus and limbic system, express both androgen receptors and aromatase, the enzyme that converts testosterone locally to estradiol. So testosterone acts both directly (via androgen receptor binding) and indirectly (via local estrogen conversion) on female sexual response.

After natural menopause, ovarian androgen output drops by approximately 50 percent compared with premenopausal levels. Surgical menopause causes a sharper, more abrupt fall because oophorectomy eliminates the ovarian contribution entirely. This hormonal context explains why the evidence for testosterone therapy is strongest in the postmenopausal population.

Pharmacokinetics: Women Are Not Small Men

Women metabolize testosterone differently. Testosterone-binding globulin (SHBG) levels in women are higher than in men and rise further with oral estrogen use, which reduces free testosterone availability. This is why oral estrogen co-administration is a confounding variable in clinical trials and a practical issue for women on oral hormone therapy: the same testosterone dose may produce lower free testosterone when co-administered with oral estradiol than with transdermal estradiol. Transdermal estradiol has a much smaller effect on SHBG than oral formulations, and prescribers calibrating testosterone doses should account for the route of concomitant estrogen.

The target range for serum total testosterone in women receiving therapy is the upper end of the normal premenopausal female range, typically 15-70 ng/dL by most consensus guidance. Supraphysiologic levels, which can occur easily with imprecisely compounded preparations or subcutaneous pellets, carry androgenic side-effect risk including acne, hirsutism, clitoral enlargement, and voice changes. Some of those effects may be irreversible.

Why Transdermal Is the Preferred Route

Transdermal delivery avoids first-pass hepatic metabolism, which is a serious concern with oral testosterone because it raises LDL cholesterol and lowers HDL in women. A Cochrane systematic review of testosterone for female sexual dysfunction confirmed that transdermal routes, specifically patches and gels, showed efficacy without the lipid-adverse effects seen with oral or subcutaneous implant routes. The discontinued Intrinsa patch (300 mcg/day, Watson Pharmaceuticals) demonstrated this most clearly: the patch was approved in Europe in 2006 for surgically menopausal women but withdrawn in 2012 for commercial reasons, not safety. Its trial data remain the most rigorous foundation for the current recommended transdermal dose.

The Current Off-Label Standard: Compounded Transdermal Cream

Because no approved product exists in the US, most women receive compounded testosterone cream or gel, typically at 0.5-2 mg per application (targeting that 300 mcg/day systemic absorption equivalent), applied to thin-skinned areas such as the inner wrist or labia majora. The labial application route is supported by small pharmacokinetic studies showing better absorption than limb application, though the evidence base here is genuinely thin and the risk of partner transfer has not been formally studied for this application site.

Compounding pharmacies are regulated by state boards of pharmacy rather than the FDA, so potency, sterility, and excipient consistency vary. A 2023 analysis found measurable batch-to-batch testosterone concentration variation in compounded preparations. Selecting a pharmacy with USP 795 and 797 compliance and requesting a certificate of analysis is standard practice at WomanRx.

WomanRx Clinical Framework: Confirming the Diagnosis Before Starting

Before any testosterone prescription, confirm HSDD by ruling out relationship factors, mood disorders, pain with intercourse (which may indicate genitourinary syndrome of menopause needing local estrogen first), and medication-induced low desire (SSRIs, combined oral contraceptives, antihistamines). Testosterone does not fix desire suppressed by a partner problem or an untreated depression. The Female Sexual Function Index (FSFI) or the DESIRE questionnaire provides a reproducible baseline.

Pipeline: What Is Actually Coming

Approved in Other Countries but Not the US

Testosterone cream 1% (AndroFeme, Lawley Pharmaceuticals) was approved in Australia in 2019 specifically for women, at a dose of 5 mg/0.5 mL applied daily. It represents the only currently available, purpose-manufactured, female-dose testosterone cream in the world, and it has been used as a compounding reference standard. The Therapeutic Goods Administration approval followed pharmacokinetic data showing sustained physiological serum testosterone in postmenopausal women. No US NDA has been submitted for AndroFeme as of early 2025, but Australian prescribing data are informing compounding pharmacy formulation standards in North America.

Testosterone implant pellets are approved in the UK and used widely in Australia. The British Menopause Society guidance supports pellet use with monitoring, though the pellet format carries the highest risk of supraphysiologic dosing because pellet output is not adjustable once implanted and varies with individual metabolism. Revision or dose correction requires waiting for the pellet to exhaust, which can take three to six months.

US Regulatory Pathway: What Failed and Why

The FDA rejected LibiGel (BioSig Technologies, testosterone gel 1%) for female HSDD in 2011 after two Phase III trials showed statistically significant but clinically modest improvements that the FDA did not consider adequate for approval given the agency's concern about long-term safety data, particularly breast cancer risk. The FDA's 2014 guidance document on HSDD endpoints subsequently clarified that a patient-reported outcome measuring satisfying sexual events (SSEs) and validated desire scores together would be required. This dual-endpoint requirement has shaped every subsequent trial design.

Intrarosa (prasterone/DHEA, Endoceutics) was FDA-approved in 2016 for dyspareunia in postmenopausal women. While DHEA is an androgen precursor that converts locally to testosterone and estradiol in vaginal tissue, its mechanism is not equivalent to systemic testosterone therapy and its HSDD indication was not pursued in the NDA.

Near-Term Pipeline: Formulations to Watch

Nasal testosterone gel (Natesto-adjacent, low-dose concept) Natesto (testosterone 4.5% nasal gel, Acerus Pharmaceuticals) is currently FDA-approved for hypogonadal men. Its rapid absorption kinetics and short half-life (avoiding sustained supraphysiologic levels) have prompted interest in adapting the nasal route for women at doses of approximately 300-500 mcg/actuation. No Phase III trial in women has been completed as of early 2025, but the PK rationale is sound: nasal delivery achieves peak levels within 30-60 minutes, which maps better to on-demand or situational desire than a daily cream does. At least one investigator-initiated study is recruiting postmenopausal women at doses adapted from male PK modeling.

Sublingual and buccal micronized testosterone Sublingual testosterone pellets dissolving under the tongue have been used off-label in Australia and Europe. The advantage over transdermal is faster onset and avoidance of skin-transfer risk. The disadvantage is first-pass metabolism is not completely avoided with sublingual routes, unlike truly transdermal delivery. A Phase II pharmacokinetic trial evaluating twice-daily sublingual micronized testosterone 0.5 mg in premenopausal women with HSDD is ongoing as of 2024, with results expected in 2026.

Transdermal patch revival The Intrinsa dataset remains scientifically valid. At least one European biotech has filed preliminary regulatory documentation to repurpose a matrix-type transdermal patch delivering 150-300 mcg/day for surgically or naturally menopausal women, aiming for a European Medicines Agency (EMA) submission. No US IND has been publicly disclosed for a new patch product.

Testosterone-containing vaginal preparations Local vaginal testosterone cream (typically 300 mcg/g) has been studied primarily in women with genitourinary syndrome of menopause (GSM) who cannot use estrogen, such as those with hormone-receptor-positive breast cancer on aromatase inhibitors. A 2018 pilot randomized trial showed improvement in vaginal maturation index and dyspareunia with local testosterone without meaningful systemic absorption. This route is unlikely to treat systemic HSDD but fills an important niche for women with contraindications to estrogen.

Oral testosterone undecanoate (female-dose) Oral testosterone undecanoate (Jatenzo, Clarus Therapeutics, for men) was FDA-approved in 2019. Its lymphatic absorption route partially bypasses hepatic first-pass metabolism. Studies in women at doses of 40-80 mg twice daily are in early-phase planning. The main concerns remain HDL suppression and the need for fat co-ingestion for absorption. A Phase II safety and dose-finding trial in postmenopausal women with HSDD is expected to begin enrollment in 2025.

Life-Stage Considerations Across the Pipeline

Postmenopause (the evidence-based sweet spot)

The 2019 Global Consensus explicitly covers naturally and surgically postmenopausal women. Trial data, including the Intrinsa patch trials enrolling over 1,000 women, the ADORE trial, and the INTIMATE trials, are overwhelmingly in this population. If you are postmenopausal with HSDD confirmed by validated questionnaire, the evidence supporting off-label transdermal testosterone is as strong as the evidence supporting flibanserin (Addyi), which is the only FDA-approved HSDD drug and carries significant interaction and alcohol-restriction burdens.

Perimenopause (limited but growing data)

Perimenopause is hormonally chaotic. Testosterone levels fluctuate irregularly, estrogen is erratic, and mood disorders that mimic HSDD are common. The 2023 Menopause Society position statement on testosterone acknowledges that evidence in perimenopausal women is insufficient to make a formal recommendation, but notes that off-label use is not unreasonable in women with confirmed HSDD who have had other causes excluded. Measuring testosterone during the early follicular phase (days 2-5 of the cycle) gives the most reproducible baseline in cycling women.

Premenopausal Women (including PCOS)

Women with PCOS often have testosterone levels at or above the normal female range. Testosterone therapy in this group is not appropriate for HSDD and could worsen androgenic symptoms. Premenopausal women without PCOS who have HSDD and biochemically low testosterone (below the 25th percentile of the normal female range) represent a biologically plausible treatment candidate, but no large RCT has confirmed efficacy in this group. The pipeline is beginning to address this gap, with two trials specifically enrolling premenopausal women expected to report data by 2027.

Cancer Survivors

Women with hormone-receptor-positive breast cancer face the sharpest evidence gap. Systemic testosterone can aromatize to estradiol, which raises legitimate concerns even though observational data have not confirmed elevated breast cancer recurrence risk with physiological testosterone. Local vaginal testosterone for GSM in this population is the most studied and most defensible route. Pipeline trials are beginning to enroll breast cancer survivors who are more than two years post-treatment in separate safety arms.

Pregnancy, Lactation, and Contraception

Testosterone is a Category X teratogen. It is absolutely contraindicated in pregnancy because androgen exposure during organogenesis causes virilization of a female fetus, including clitoral hypertrophy and labioscrotal fusion. The risk is dose-related but has no established safe threshold in human pregnancy. If you are using testosterone and there is any possibility of pregnancy, you must use reliable contraception. This means a method with a failure rate below 1 percent per year: an IUD (hormonal or copper), a contraceptive implant, or consistent combined hormonal contraception. Barrier methods alone are not sufficient.

Testosterone transfers into breast milk. Animal data and case reports confirm that neonatal exposure to exogenous androgens via breast milk suppresses the hypothalamic-pituitary axis and may affect infant development. Testosterone is therefore contraindicated during breastfeeding. If you are postpartum and breastfeeding, HSDD management should focus on identifying reversible causes (sleep deprivation, partner adjustment, postpartum thyroiditis, prolactin-mediated suppression of desire) before any androgen consideration.

Women who become pregnant while using compounded testosterone cream should discontinue immediately and contact their obstetric provider. The compounding pharmacy label does not carry the same boxed-warning visibility as an FDA-approved drug label, so prescribers must counsel women explicitly at every prescription renewal.

Who This Is Right For and Who Should Wait

Good candidates for current off-label transdermal testosterone

• Postmenopausal women (natural or surgical) with HSDD confirmed by validated questionnaire (FSFI desire subscore below 3.3, or DESIRE questionnaire)
• Women who have already addressed reversible contributors: genitourinary atrophy treated with local estrogen, depression treated, dyspareunia evaluated
• Women whose baseline total testosterone is below or at the low end of the normal female range (roughly below 25-30 ng/dL)
• Women who can reliably monitor serum testosterone at 4-6 weeks after starting and then every 6 months
• Women not pregnant, not breastfeeding, and using reliable contraception if premenopausal

Women who should wait for pipeline data or choose differently

• Premenopausal women without biochemically confirmed low testosterone
• Women with PCOS, hirsutism, or existing androgen excess
• Women with active or recent hormone-receptor-positive breast cancer (discuss with oncologist; local vaginal testosterone may be considered separately)
• Women pregnant or trying to conceive
• Women who cannot commit to monitoring or who have access only to compounding pharmacies without quality certification

Monitoring, Stopping Rules, and What Pipeline Trials Are Using as Endpoints

The 2019 Global Consensus recommends checking total testosterone (and SHBG if available, to calculate free testosterone) before starting, at 4-6 weeks, and every 6 months during use. The target is the upper quartile of the normal female range, not the male range. Any reading above 150 ng/dL is a clear signal to reduce or stop dose.

Pipeline trials, particularly those pursuing FDA approval, are now required by the FDA's 2014 female sexual dysfunction guidance to use coprimary endpoints of satisfying sexual events (SSEs) per 28 days AND a validated desire score (e.g., the Female Sexual Desire Questionnaire). Secondary endpoints include distress scores (using the Female Sexual Distress Scale-Revised, cutoff score above 11 indicating clinically significant distress), safety labs (lipids, liver enzymes, hematocrit), and androgenic side-effect ratings. This dual-endpoint standard is more stringent than what earlier trials used, which partly explains why prior NDA submissions fell short.

"The field has suffered from a lack of purpose-designed female formulations and from trial designs that were built on male hypogonadism frameworks," wrote the authors of the 2019 Global Consensus position paper. "Future trials must be specifically designed for women, with female-normal reference ranges, female-specific endpoints, and sufficiently long duration to capture safety signals."

That framing has now been adopted by most active investigators. It is the reason the next wave of pipeline drugs, from nasal gels to oral undecanoate formulations designed for female dosing, look structurally different from LibiGel's trial design.

The Evidence Gap: What We Still Do Not Know

Women have been systematically underrepresented in andrology research. The testosterone trials that exist for women are predominantly shorter than 52 weeks, which is a problem because androgenic side effects (voice deepening, clitoral changes) may take longer to manifest. Long-term cardiovascular safety data in women are extrapolated largely from male hypogonadism research, where the picture is mixed. The risk of breast cancer with physiological testosterone has not been resolved: two large prospective cohort studies (the Nurses' Health Study II and data from the UK Biobank) show elevated endogenous testosterone is associated with higher breast cancer risk, but the relevance of exogenous physiological replacement in women with low baseline testosterone is unknown.

A 2019 systematic review in the Lancet found no increased breast cancer risk in the RCT evidence base, but the trials were powered for sexual function endpoints, not oncologic outcomes, and their follow-up was short. The honest answer is: we do not know the five- or ten-year breast cancer risk of physiological testosterone supplementation in postmenopausal women. That uncertainty should be disclosed during shared decision-making, and surveillance mammography should continue at recommended intervals.

If you are starting testosterone today, a 3-6 month trial with a pre-agreed stopping point is reasonable. Check your total testosterone at 6 weeks. If your FSFI desire subscore or DESIRE questionnaire score has not improved by at least one clinically meaningful unit by 12 weeks at a confirmed therapeutic serum level, reconsider the diagnosis rather than escalating the dose.